Document is current
Any future updates will be listed below
-
Authors
Martinez Chanza, Nieves https://orcid.org/0000-0002-2340-7415
Xie, Wanling
Issa, Majd
Dzimitrowicz, Hannah
Tripathi, Abhishek https://orcid.org/0000-0002-5198-0673
Beuselinck, Benoit
Lam, Elaine
Zakharia, Yousef
Mckay, Rana
Shah, Sumit
Mortazavi, Amir
R. Harrison, Michael
Sideris, Spyridon
Kaymakcalan, Marina D
Abou Alaiwi, Sarah
Nassar, Amin H https://orcid.org/0000-0002-8084-9105
Nuzzo, Pier Vitale https://orcid.org/0000-0002-5618-8079
Hamid, Anis
K Choueiri, Toni https://orcid.org/0000-0002-9201-3217
C Harshman, Lauren https://orcid.org/0000-0002-7636-1588
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02928406 at ClinicalTrials.govnct03656627 at ClinicalTrials.govDocuments that mention this clinical trial
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
https://doi.org/10.1136/jitc-2022-005977
Final results from SAUL, a single-arm international real-world study of atezolizumab (atezo) in 1004 patients (pts) with pretreated locally advanced/metastatic urinary tract carcinoma (UTC).
https://doi.org/10.1200/jco.2023.41.16_suppl.4569
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
https://doi.org/10.1136/jitc-2020-000538
nct03816345 at ClinicalTrials.govDocuments that mention this clinical trial
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
https://doi.org/10.1136/jitc-2020-000538
Documents that mention this clinical trial
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
https://doi.org/10.1136/jitc-2019-000356
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
https://doi.org/10.1136/jitc-2021-002567
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
https://doi.org/10.1136/jitc-2020-000538
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658
- License Information
